VPRIV is a first-line option for your treatment-naïve patients1,2
The recommended starting dose for treatment-naïve patients 4 years of age and older is 60
U/kg once every other week as a 60-minute IV infusion.1 VPRIV
should be administered under the supervision of a healthcare professional.1
*Treatment-naïve: patients who had not received disease-specific
treatment for at least 30 months prior to starting VPRIV3
12-MONTH PARALLEL-DOSE: STUDY 032
STUDY 032 DESIGN (N=25)3
R (N=25)
VPRIV 45 U/KG
EOW (n=13)
VPRIV 60 U/KG
EOW (n=12)
PRIMARY OBJECTIVE
Change in hemoglobin concentration from baseline to 12 months in
the 60 U/kg treatment group.3
SECONDARY OBJECTIVES
Included changes from baseline to 12 months in hemoglobin
concentration in the 45 U/kg treatment group; and changes from baseline to 12 months in platelet
count, and spleen and liver volumes, for both treatment groups.3
At 12 months, VPRIV improved hemoglobin concentration
with clinically relevant differences from baseline observed. Differences from baseline were observed for secondary
objectives.3
PRIMARY OBJECTIVE
HEMOGLOBIN CONCENTRATION
Mean hemoglobin concentration at baseline: 10.6 g/dL1
Mean change at 12 months: +2.4 g/dL ± 0.3 (SE)1,3
SECONDARY OBJECTIVES
PLATELET COUNT
Mean platelet count at baseline: 97 × 109/L1
Mean change at 12 months: +51 × 109/L ± 12 (SE)1,3
SPLEEN VOLUME
Mean spleen volume at baseline: 2.9% of body weight1
Mean change at 12 months: −1.9% ± 0.5 of body weight1
LIVER VOLUME
Mean liver volume at baseline: 3.6% of body weight1
Mean change at 12 months: −0.84% ± 0.33 of body weight1
Mean change (%) from baseline3
Increasing hemoglobin and platelet counts
Decreasing spleen and liver volumes
HEMOGLOBIN CONCENTRATION
PLATELET COUNT
SPLEEN VOLUME
LIVER VOLUME
+23%
n=12
+66%
n=12
−50%
n=12
−17%
n=12
†This decrease was not
statistically significant
after adjusting for
multiple tests
100
50
0
0
−50
−100
EOW, every other week; R, randomized; SE, standard error
IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions, including anaphylaxis, have occurred. The most
serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.
Hypersensitivity reactions were the most commonly observed adverse reactions in patients treated
with VPRIV in clinical studies. Patients were not routinely pre-medicated prior to infusion of
VPRIV.
IMPORTANT SAFETY INFORMATION
INDICATION
VPRIV® (velaglucerase alfa) for injection is indicated for long-term enzyme
replacement therapy (ERT) for patients with type 1 Gaucher disease.
IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions, including anaphylaxis, have occurred. The most serious
adverse reactions in patients treated with VPRIV were hypersensitivity reactions.
Hypersensitivity reactions were the most commonly observed adverse reactions in
patients treated with VPRIV in clinical studies. Patients were not routinely pre-medicated prior to infusion of
VPRIV. The most commonly observed symptoms of hypersensitivity reactions were: headache,
dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia. Hypersensitivity reactions
in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV
infusion, including one case of anaphylaxis. Generally the reactions were mild and, in treatment-naïve patients,
onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.
Additional hypersensitivity reactions of chest discomfort, dyspnea, pruritus and vomiting have been reported in
post-marketing experience. In some cases vomiting can be serious, requiring hospitalization and/or drug
discontinuation.
As with any intravenous protein product, hypersensitivity reactions are possible,
therefore, appropriate medical support, including personnel adequately trained in cardiopulmonary
resuscitative measures and access to emergency measures, should be readily available when VPRIV is administered. If
anaphylactic or other acute reactions occur, immediately discontinue the infusion of VPRIV and initiate
the appropriate medical treatment.
Management of hypersensitivity reactions should be based on severity of the
reaction, such as slowing the infusion rate, treatment with medications such as antihistamines, antipyretics
and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. In cases where
patients have exhibited symptoms of hypersensitivity to velaglucerase alfa or excipients in the drug product or
to other enzyme replacement therapy, pre-treatment with antihistamines and/or corticosteroids may prevent
subsequent reactions.
The most common adverse reactions during clinical studies (in ≥10% of patients)
were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain,
prolonged activated partial thromboplastin time (aPTT), fatigue/asthenia, and pyrexia. In clinical studies, the
overall frequency of adverse events was generally higher in the population naïve to enzyme replacement therapy
(ERT) than in the population switched from imiglucerase to VPRIV.
The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and
adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Adverse
reactions more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash,
prolonged aPTT, and pyrexia.
The adverse reaction profile in elderly patients was consistent with that
previously observed across pediatric and adult patients. In general, dose selection for an elderly patient should
be approached cautiously, considering comorbid conditions. As with all therapeutic proteins, there is a
potential for immunogenicity. In clinical studies, 1 of 54 (2%) enzyme treatment-naïve patients treated with VPRIV
developed IgG class antibodies (neutralizing in an in vitro assay). One
additional patient developed IgG antibodies to VPRIV during an extension study. It is unknown if the
presence of IgG antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune
response to other ERTs who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.
Please click here
for Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact
Medical Information at 1-866-888-0660, option 2 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
For assistance with medical inquiries about VPRIV, please contact Takeda at
1-877-TAKEDA-7 (1-877-825-3327), or email medinfous@takeda.com.
YOU ARE ABOUT TO LEAVE THIS SITE.
You are now being taken to an external website that is not under the control of
Takeda. We have no control over the nature, content, and availability of those sites.
The inclusion of any links does not necessarily imply a recommendation or endorsement of the views
expressed within them.
Do you wish to continue and leave this website?
ARE YOU A US HEALTHCARE PROFESSIONAL?
You are being directed to hcp.vpriv.com.
This website is intended for healthcare professionals residing in the US only.
I am an HCP residing in the US
(Proceed to Professional site)
I am not an HCP residing in the US
(Proceed to Patient site)
